MURINE HEMATOPOIETIC CELLS WITH PRE-B OR PRE-B/MYELOID CHARACTERISTICS ARE GENERATED BY IN VITRO TRANSFORMATION WITH RETROVIRUSES CONTAINING fes, ras, abl, and src ONCOGENES

BY KEVIN L. HOLMES,* JACALYN H. PIERCE,† WENDY F. DAVIDSON,§ AND HERBERT C. MORSE III*

From the *Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases; the †Laboratory of Cellular and Molecular Biology; and the §Laboratory of Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892

The development of in vitro hematopoietic assay systems has permitted the identification of specific cell subpopulations that are susceptible to transformation induced by retroviruses containing different oncoproteins. In particular, studies using a colony-forming assay that is dependent upon the presence of 2-ME have revealed that pre-B cells were transformed when cultures were infected with viruses containing abl or fes, oncoproteins that code for tyrosine-specific protein kinases (1, 2). By comparison, cultures infected with viruses containing bas, H-ras, or K-ras, oncoproteins that code for proteins with guanidine diphosphate (GDP)1-binding activity (3), produced transformed hematopoietic cell lines that lacked characteristics of cells in the B, T, or erythroid cell lineages (4). Although one continuous line was shown to have myeloid characteristics (5), most of the cell lines transformed by ras-containing retroviruses expressed high levels of terminal deoxynucleotidyl transferase (TdT) activity, suggesting that they were derived from cells at an early stage within the lymphoid differentiation pathway. Transformed lines with characteristics similar to those of the ras-induced neoplasms were also obtained from hematopoietic cell cultures infected with a murine recombinant retrovirus containing the src oncogene that, like abl and fes, codes for a tyrosine-specific kinase (6).

To more clearly define the characteristics of the cell populations transformed by the bas, H-ras, K-ras, and src oncogenes, continuous clonal cell lines produced from infected bone marrow and fetal liver cultures were examined for expression of lineage-specific cell-surface antigens, expression of cytoplasmic μ chain (cμ), and the organization of Ig heavy and light chain genes. The results show that cell lines with characteristics of pro-B and pre-B cells were obtained from cells infected with viruses containing bas, H-ras, K-ras, and src, as well as abl and fes. In addition, two cell lines transformed by ras-containing viruses were found to

1 Abbreviations used in this paper: ABL, Abelson MuLV; BMSV, Balb murine sarcoma virus; cμ, cytoplasmic μ chain; FeSV, Snyder Theilen feline sarcoma virus; FMF, flow microfluorometry; FU, fluorescence units; GDP, guanidine diphosphate; HMSV, Harvey murine sarcoma virus; KMSV, Kirsten sarcoma virus; MRSV, murine Rous sarcoma virus; MuLV, murine leukemia virus; NSE, nonspecific esterase; sIg, surface immunoglobulin; TdT, terminal deoxynucleotidyl transferase.
Purchased from New England Nuclear (Boston, MA).

§PEM, Peritoneal exudate macrophage.

coeexpress antigens usually restricted to the B cell or myeloid pathways of differentiation. Detailed analyses of these two lines suggest that the initial transforming event giving rise to these lines occurred in a precursor common to the B cell and myeloid lineages.

Materials and Methods

Cell Lines. The cell lines examined were obtained from cultures of fetal liver cells or bone marrow cells from 2–3-wk-old NFS/N mice that were infected as described (4) with amphotropic murine leukemia virus (MuLV) or Moloney MuLV pseudotypes of replication-defective retroviruses containing the Rous sarcoma virus (MRSV) src oncogene (6), the Harvey sarcoma virus (HMSV) H-ras oncogene (4), the BALB sarcoma virus (BMSV) bas oncogene (4), the Kirsten sarcoma virus (KMSV) K-ras oncogene, the Snyder-Theilen feline sarcoma virus (FeSV) fes oncogene (2), or the Abelson murine leukemia virus (ABL) abl oncogene. Individual colonies appearing in the soft agar cultures were harvested, cultured in suspension in microtiter wells, and grown to bulk cultures, usually with the use of adherent feeder layers. Cell lines expanded in the presence of feeder layers were recloned in soft agar before further characterization. All the cell lines were shown to contain and express the oncogenes used in their induction (2, 4–6).

Flow Microfluorometry (FMF). FMF analyses were performed on a FACS II (Becton Dickinson and Co., Sunnyvale, CA) using established techniques (7) in which viable cells were electronically gated by narrow forward-angle light scatter and uptake of propidium iodide (8). Cells were reacted with the panel of monoclonal and alloantibodies shown in Table I and with FITC-labeled goat anti-mouse κ antibodies (Southern Biotechnology Assoc., Birmingham, AL) to detect surface Ig (sIg). Binding of antibodies to Lyb-8.2, Ia, and Ly-17.1 was detected using a FITC-labeled goat anti-mouse IgG (Southern Biotechnology Assoc.). Binding of antibodies to Mac-2 and Mac-3 was detected using a FITC-labeled rabbit anti-rat IgG (Zymed Laboratories, San Francisco, CA). All other reagents used were directly labeled with FITC.

Two-color FMF was performed using FITC-labeled anti-Mac-1 and biotin-labeled anti-Lyb-2.1 or anti-Ly-5 (B220) (prepared in our laboratory) and Texas Red–labeled avidin (Cappel Laboratories, Malvern, PA). To prevent binding of antibodies via their Fc...
portions, $10^6$ cells were incubated with 10 μg of unlabeled anti-Fc γ receptor (clone 2.4.G2, reference 13) before incubation with labeled antibodies.

**Cell Sorting.** Cells from the HHSV-infected line, HAFTL3, and the BMSV-infected line, BAMC1, were sorted into Mac-1+ (Mac-1'-sorted) or Mac-1- (Mac-1"-sorted) populations using the FACS II cell sorter and/or were single cell-cloned by sorting Mac-1+ (Mac-1'-cloned) or Mac-1- (Mac-1"-cloned) cells into individual wells of 96-well round bottomed microtiter plates using an Epics V (Coulter Electronics, Hialeah, FL) flow cytometry system.

**Measurement of Ig μ and κ Chains.** The amount of mouse Ig μ and κ chains present in cells was determined by competition RIA, as described previously (2).

**Molecular Assays.** High molecular weight DNA was prepared, digested with restriction enzymes, separated on 0.8% agarose gels, and transferred to nitrocellulose using established techniques. Southern blots were hybridized with 32P-labeled DNA probes at 65°C in a buffer containing 3x SSC, 10% dextran sulphate, 10× Denhardt's solution, 0.1% SDS, 5 mM EDTA, and 50 μg/ml salmon sperm DNA. Blots were washed successively in 3x SSC at 37°C for 20 min, 1x SSC at 65°C for 10 min and 0.2x SSC at 65°C for 30 min, and analyzed by autoradiography. Two probes were used, Jμ, a 1.96-kb Bam HI/Eco RI fragment of the BALB/c germline Jμ region (21) and Jκ, a 2.8-kb Hind III/Hind III fragment of pEC, (22).

**Assays for Macrophage Function.** The assay for nonspecific phagocytosis was carried out in chamber slides (4008; Miles Laboratories Inc., Naperville, IL). Cells were inoculated with 100 μl of 1-μm latex beads (15711; Polysciences, Inc., Warrington, PA) and incubated at 37°C for 3 h. Slides were washed in PBS, stained with Wright's-Giemsa and cells were scored for bead ingestion at × 100 magnification. Lysozyme was assayed by the lysoplate assay using egg white lysozyme as a standard (5). Levels of lysozyme were expressed in μg per $10^6$ cells per 24 h. The presence of nonspecific esterase was determined by cytochemical staining using a Sigma Chemical Co. (St. Louis, MO) research kit (5).

**Results**

**Phenotypic Analyses.** Cell lines were analyzed by FMF for expression of cell surface antigens characteristic of cells in the B, T, and myeloid lineages (Table I). The results showed that all of the transformed cell lines, irrespective of the oncogene-containing retrovirus used in their induction, had characteristics of early cells in the B lymphocyte lineage (Table II). The phenotypes exhibited by the different lines correspond to several stages of maturation in a recently proposed scheme of B cell development (23, 24; Fig. 1). In this scheme, it was postulated that Ly-17+, Lyb-2+ cells, provisionally termed pro-B cells, are the progenitors of Ly-5(B220)+ large pre-B cells defined in other studies (11). Large pre-B cells differentiate into ThB+ small pre-B cells, which become mature B cells with the acquisition of sIg (11). Expression of Ia antigens by B cells occurs either simultaneously with or subsequent to sIg expression (25, 26).

In the present study, two cell lines (BASC6 and HRC3) were Ly-17+, Lyb-2+, but Ly-5(B220)-, ThB+, Ia-, and sIg-, a phenotype that corresponds to the pro-B cell stage of differentiation (Table II and Fig. 1). 14 of the lines were Lyb-2+ and uniformly Ly-5(B220)+, or contained subpopulations of Ly-5(B220)+ cells and were 'ThB+', sIg-, and Ia-, and therefore corresponded to the large pre-B cell stage of differentiation. Two lines Y1C1 and HAFTL3, contained subpopulations of ThB+ cells and Ia+ cells. Finally, two lines (HAFTL1 and FE2NC1) were Ly-17+, Lyb-2+, Ly-5(B220)+, and Ia4+/−, sIg+, and ThB+ a phenotype with no documented counterpart in studies of normal or malignant cells within the B lymphocyte lineage (25, 26). This finding raises the possibility that Ia may sometimes be expressed before ThB or sIg during normal B cell maturation.
### Table II

**Analysis of MuLV-infected Bone Marrow and Fetal Liver Cells**

| Virus | Cell line | Cell source | Cell surface antigens* | Ig gene organization† |
|-------|-----------|-------------|------------------------|------------------------|
|       |           |             | Thy-1                  | sIg§                    | µ† | JH | JK |
| ABL   | Y1C1      | BM          | −                      | −/−                    | −  | ++ | ++ |
| AAC6  | BM        | −           | −                      | −/−                    | −  | ++ | ++ |
| BMSV  | BASC6     | BM          | −                      | −                      | −  | ++ | ++ |
|       | BAC14     | BM          | −                      | +/−                    | ++ | ++ | ++ |
|       | BAMC1     | BM          | −                      | −                      | ++ | ++ | ++ |
| FESV  | FE2NC1    | BM          | −                      | −/−                    | +++| ++ | ++ |
|       | FEMCL     | BM          | −                      | −                      | ++ | ++ | ++ |
| HHSV  | HAFTL3    | FL          | −                      | −/−                    | +++| ++ | ++ |
| HS1C5 | BM        | −           | −                      | +/−                    | ++ | ++ | ++ |
| HRC3  | BM        | −           | −                      | −                      | ++ | ++ | ++ |
| HAFTL1| FL        | −           | −                      | −                      | ++ | ++ | ++ |
| HAFTL2| FL        | −           | −                      | −                      | ++ | ++ | ++ |
| KMSV  | KFFT1.1   | BM          | −                      | −                      | +  | +++| ++ |
| MRSV  | JP1       | BM          | −                      | −                      | ++ | +++| ++ |
|       | JP4-2     | BM          | −                      | +                      | +++| ++ | ++ |
|       | JP5       | BM          | −                      | +                      | ++ | ++ | ++ |
|       | JP4-1     | BM          | +                      | +                      | ++ | ++ | ++ |
|       | JP2       | BM          | −                      | +                      | ++ | ++ | ++ |
|       | JP7       | FL          | −                      | +                      | ++ | ++ | ++ |

* FMF analysis in which observed fluorescence is related to staining intensity observed with normal spleen cells using the following scheme: −, nonreactive; +, reactive with a mean intensity more than 100 fluorescence units (FU) less than the mean intensity of normal cells; ++, reactive with a mean intensity equal to the mean intensity ± 100 FU of normal cells; and ++++, reactive with a mean intensity more than 100 FU greater than the mean intensity of normal cells; (+), staining only slightly above unstained controls; +/−, heterogeneity of staining with >50% of the population reactive with the antibody; or −/+, <50% reactivity.

† Bone marrow or fetal liver cells were infected in vitro with ABL, MuLV, BMSV, HHSV, or KMSV, FeSV or MRSV.

‡ sIg detected with Goat anti-λ antibodies.

§ Ig µ chain as determined by RIA.

### Notes

- Rearrangement of Ig genes detected with 32P-labeled probes specific for Ig heavy chain (J_H) and with light chain (J_λ) genes. G, germline configuration; R, rearranged.
- Indicates hybridization of more than two rearranged heavy chain fragments with the J_μ probe.
The majority of the lines (16/20), including both of the pro-B cell lines, were Ly-1+, a finding consistent with previous reports that expression of Ly-1 occurs very early during the development of the Ly-1+ B cell lineage (27–30). In addition, all the cell lines but two expressed the antigen recognized by the mAb 6C3, recently shown to be expressed at low levels on some normal bone marrow cells (31) and at high levels in many MuLV-induced B and pre-B cell lymphomas (reference 20 and unpublished observations). The pattern of expression of Lyb-8.2 and Ly-5(B220) on these lines suggests that these antigens may be expressed simultaneously during B cell differentiation (see Fig. 1). The observation that all of the lines expressed Ly-17.1, recently shown to be a polymorphic determinant of the Fcγ receptor (14), is consistent with previous suggestions that this antigen may be expressed very early in B cell differentiation (23). It is noteworthy that two cell lines, FEMCL and JP4-1, expressed Thy-1, a cell surface antigen usually associated with the T cell lineage among murine hematopoietic cells, but that may also be expressed during myeloid differentiation (32, 33).

Two cell lines, HAFTL3 and BAMC1, were of particular interest. Cells from these lines were uniformly Lyb-2+, Ly-5(B220)+, and ThB-, corresponding to the large pre-B cell stage of differentiation, yet both lines were Mac-1−, i.e., contained subpopulations (10–15%) of Mac-1+ cells (see Table II legend). Expression of Lyb-2 and Ly-5(B220) by BAMC1 was surprising, since this line was previously shown to be Mac-1+ and to express other characteristics consistent with immature cells of the myeloid lineage (5).

**Ig Gene Organization and Expression.** High molecular weight DNA extracted from the cell lines was digested with Eco RI or Hind III and hybridized with the JH or the Jκ probes, respectively. Results of hybridization with the JH probe showed that all of the lines had undergone rearrangements of this locus on at least one of the two chromosomes bearing JH genes (Table II and Fig. 2). Hybridization with the Jκ probe showed that only three cell lines exhibited rearrangements of k light chain genes (Table II and Fig. 3). The results obtained with both probes yielded no evidence that any of the lines, in particular in HAFTL3 and BAMC1, were not monoclonal. Productive Ig gene rearrangements resulting in production of κ or μ molecules were observed only in three cell lines: AAC6, FE2NCI, and FEUC (Table II). No κ chain protein was detected in any of the lines, including those that had rearrangements at the κ gene locus.

**Analysis of Mac-1+ and Mac-1− Subpopulations of HAFTL3 and BAMC1 Obtained**
Figure 2. Southern blot of Eco RI-digested DNA from: NFS spleen (1), NFS liver (2), HAFTL1 (3), BAMCI (4), JP2 (5), AAC6 (6), HAFTL2 (7), Y1C1 (8), JP7 (9), HSIC5 (10), HRC3 (11), FEUC (12), FE2NCI (13), and KFFTLLI (14) hybridized with the JH probe.

by Cell Sorting. The observations that HAFTL3 and BAMCI were uniformly positive for expression of the B lineage antigens Lyb-2 and Ly-5(B220) but Mac-1^-+ (Table II) indicated that subpopulations of both cell lines simultaneously expressed both myeloid and B lineage cell-surface antigens. This was confirmed by two-color FMF analyses of HAFTL3 and BAMCI for expression of Mac-1 in relation to Lyb-2.1 or Ly-5(B220) (data not shown). To determine whether the subpopulations of Lyb-2^+, Ly-5(B220)^+, Mac-1^-, and Lyb-2^+, Ly-5(B220)^+, Mac-1^+ cells in HAFTL3 and BAMCI could be propagated as phenotypically stable cell lines, HAFTL3 and BAMCI were sorted by FMF into nonoverlapping Mac-1^- and Mac-1^- populations. After expansion in liquid culture, both the Mac-1^-sorted and Mac-1^-sorted HAFTL3 lines were Mac-1^- when analyzed by FMF. To determine whether the observed heterogeneity was due to contamination between sorted populations, HAFTL3 Mac-1^- and Mac-1^- populations were single cell-cloned by FMF. Analysis of clones for the expression of Mac-1 using fluorescence microscopy revealed that at 1 wk after sorting (~500 cells per well), Mac-1^-cloned cells were uniformly Mac-1^-, whereas at 2 wk, 5 out of 5 clones analyzed were Mac-1^-+. FMF analysis of Mac-1^-cloned lines after expansion in culture showed that 29 of 31 clones were Mac-1^-/+ and 2 were uniformly Mac-1^+. In contrast, Mac-1^-cloned HAFTL3 cells were uniformly Mac-1^- when analyzed by fluorescence microscopy at 1 and 2 wk after sorting. 12 of 13 lines, expanded in culture and analyzed by FMF, were uniformly Mac-1^- and one was Mac-1^-+. These results showed that Mac-1^- HAFTL3 cells were derived from Mac-1^- cells. Moreover, hybridization of the JH probe with DNA prepared from
the parental HAFTL3 line and the uniformly Mac-1⁺ subclone HAFTL3-A, showed that both lines had identical J₅ rearrangements (Fig. 4).

Two HAFTL3 Mac-1⁺ subclones, HAFTL3-A and -3D10, were analyzed further for expression of Lyb-2, Ly-5(B220), and Ia; for the macrophage-lineage antigens Mac-2 and Mac-3; for production of lysozyme and nonspecific esterase (NSE); and for their ability to phagocytose latex beads (Table III). Both subclones were uniformly Ia⁺, Lyb-2⁺, and Ly-5(B220)⁺; produced high levels of lysozyme and NSE; and were phagocytic. HAFTL3-A, in comparison with HAFTL3-3D10, produced higher levels of both enzymes, was more actively phagocytic, and also expressed Mac-2, an antigen normally found on thioglycollate-elicited peritoneal macrophages (18). Both lines were Mac-3⁻. Consistent with these phenotypic and functional characteristics, HAFTL3-A had morphological features typical of a mature macrophage (Fig. 5b). In contrast, the parental HAFTL3 cells had a distinctive lymphoid morphology (Fig. 5a).

BAMC1 was originally described as a myeloid-lineage cell line (5), but attempts to obtain stable uniformly Mac-1⁺ cell lines from BAMC1 by single cell-cloning were unsuccessful. FMF analysis of 24 subclones generated from both Mac-1⁻
cloned and Mac-1+ cloned BAMC1 showed that they were either Mac-1- or Mac-1+/-. However, one Mac-1+ cloned line, BAMC1-4E10, which was Mac-1+/−, had twofold higher levels of lysozyme production than the parental BAMC1 line, and could be induced to produce higher levels of lysozyme and become >80% Mac-1+ after stimulation with the phorbol ester, PMA (data not shown).

Discussion

The results of this study show that in vitro infection of bone marrow or fetal liver cells with retroviruses containing the bas, H-ras, K-ras, src, abl, and fes oncogenes induces the transformation of early B lineage cells. Analyses of these cell lines for expression of cell-surface antigens and Ig gene organization showed that they had remarkably similar phenotypes, regardless of whether the viruses
used for infection contained oncogenes coding for tyrosine-specific kinases or GDP-binding proteins (Table II). These data confirm reports of transformation of pre-B cells by abl and fes (1, 2, 34) and significantly extend previous phenotypic characterization of ras- and src-induced hematopoietic cell transformants (4–6).

It was previously shown that infection of bone marrow or fetal liver cells with ras- or src-containing retroviruses induced the transformation of cells that were assumed to be lymphoid progenitor cells because they were sIg−, cμ−, but expressed high levels of TdT (4, 6). Ras-containing viruses also induced alterations in the growth and differentiation of myeloid cells, although only one continuous cell line, BAMC1, was isolated from these cultures (5). In the present study, extensive analyses of the ras- and src-transformants have shown that all had phenotypes characteristic of pre-B cells and that most corresponded to the large pre-B cell stage of differentiation, i.e., were Lyb-2+, Ly-5(B220)+, ThB−, and sIg+. However, two cell lines, HAFTL3 and BAMC1, contained subpopulations of Lyb-2+, Ly-5(B220)+, Mac-1+ cells that differentiated or could be induced to differentiate into cells with mature macrophage characteristics after single-cell FMF cloning.

These results raise the question as to the nature of the initial cell transformed by these oncogene-containing viruses. The target cell may be a totipotent stem cell that, under the culture conditions employed, preferentially differentiates within the B cell lineage. Although most leukemia-derived cell lines show a restricted pattern of differentiation, a transformed cell line with the capacity to differentiate within the T, myeloid, and erythroid lineages has been established from a patient undergoing treatment with deoxycoformycin, an adenosine deaminase inhibitor (35). An alternative hypothesis is that a cell with a more restricted differentiation potential may be targeted in this system. In this regard, the characteristics of most of the cell lines examined are consistent with the transformation of an early B cell progenitor giving rise to these lines.

In the clinical literature, there are numerous examples of leukemias and lymphomas that, similar to HAFTL3 and BAMC1, coexpress markers usually restricted to distinct hematopoietic cell lineages. These observations have led to two divergent interpretations. McCulloch has argued that cells with these characteristics are decidedly abnormal and that genetic misprogramming during the production of leukemic cells results in the coexpression of markers usually

**TABLE III**

*Characterization of Mac-1+ Sublines of HAFTL3*

| Line         | Cell surface antigen* | Function |
|--------------|-----------------------|----------|
|              | Ia  | Mac-1 | Mac-2 | Mac-3 | Lysozyme§ | NSE§ | Phagocytosis§ |
| HAFTL3       | −/+ | −/+   | −     | −     | <0.1     | −    | ND            |
| HAFTL3-A     | +   | +     | +     | −     | 12.5     | ++   | +++ (97%)     |
| HAFTL3-3D10  | +   | +     | −     | −     | 5.0      | +    | +(5%)         |

* Determined by FMF.

§ µg/10⁶ cells/24 h.

§ Relative amounts of reaction product as compared with a negative control.

I Average number of latex beads in cytoplasm of positive cells according to the following scheme:

+++ >75 beads per cell; +, between 5 and 25 beads per cell. Numbers in parentheses indicate the percentages of cells with >5 beads per cell.
FIGURE 5. (A) Cyto centrifuge preparation of the HML-1-terminated HAFL3 line. (B) Mac-1 subclone HAFL3-A after incubation in chamber slide with Wright–Giemsa × 1,000.
restricted to distinct hematopoietic cell lineages. He has coined the term "lineage infidelity" to describe this process (36). In contrast, Greaves et al. (37) suggest that these leukemic phenotypes reflect the persistent expression by progeny leukemic blasts of genes usually expressed only transiently by their bipotential or multipotential progenitors. They refer to this pattern of phenotypic expression in normal differentiation and leukemia as lineage promiscuity. Till (38) has raised similar arguments with respect to normal hematopoiesis.

Earlier studies of a large number of murine leukemias and lymphomas led us to propose models of normal hematopoietic differentiation (39) and more particularly of B cell differentiation (Fig. 1 and References 23, 24, 40). These models were based, in part, on the assumption that neoplasms with characteristics not represented among known normal cell phenotypes may provide important clues to lineage relationships. This view is similar to that supported by Greaves and coworkers (37), and leads to the suggestion that the results presented here and elsewhere support the hypothesis of a close developmental relationship between the B cell and myeloid lineages.

HAFTL3 and BAMC1 have characteristics thought to represent commitment to the B cell lineage, including the expression of Lyb-2 and Ly-5(B220) and the rearrangement of Ig heavy chain genes. However, these lines have retained the capacity to differentiate within the macrophage lineage. Although this may not reflect a normal differentiation pathway, it may indicate that the transformation event occurred in a common B cell/myeloid progenitor cell. We have previously suggested that this cell type be termed a pro-GMB cell, to indicate its potential for producing cells in the granulocyte, macrophage, and B cell lineages, and predicted that it would have a Ly-17+, Mac-1+ phenotype (Fig. 1 and reference 23). Cells coexpressing Lyb-2 and Mac-1, and therefore corresponding to the putative pro-B cell (Fig. 1) make up a large percentage of spleen and bone marrow cells of newborn mice (24). In addition, neonatal liver cells expressing Ly-5(B220) and possessing peroxidase positive granules have been described (41). Studies are in progress to determine the potential of these cells to differentiate within the B or myeloid lineages.

Coexpression of B lineage and myeloid antigens, similar to that seen in HAFTL3 and BAMC1, has been reported for other cell lines that were induced with murine leukemia viruses or with chemical carcinogens (23, 24, 40, 42). Among these is an Abelson MuLV-induced pre-B cell line, ABLS 8.1, which was induced to become a macrophage line with the addition of the demethylating agent, 5-azacytidine (42). Similar reports were obtained when the phorbol ester, PMA, was added to a B lineage cell line established from a patient having a t(4;11) translocation (43). In both of these cases, the original tumor cell line had rearranged Ig genes. The differentiation potential of HAFTL3 was realized without the addition of inducing agents, whereas earlier passages of BAMC1 (5) and the Mac-1+cloned line, BAMC1-4E10, showed increased expression of Mac-1 and lysozyme in response to PMA stimulation.

Studies of human leukemias also provide support for the existence of a common B/myeloid progenitor cell. The most well documented is the occurrence, in 30% of patients, of a lymphoid blast crisis (of pre-B cell phenotype) in the acute phase of chronic myelogenous leukemia (44, 45). The Philadelphia chromosome t(9;22)
translocation (46, 47) and G6PD isoenzymes (47) have been used as markers for clonality of cells involved in the lymphoid blast crisis and in the chronic phase of myelogenous leukemia. In addition, there have been reports of patients with acute leukemia in which the leukemia was either composed of a mixture of both myeloid and lymphoid cells (48), or there was a conversion from acute lymphoblastic leukemia to acute myeloid leukemia (48), or the leukemia was composed of cells that coexpressed both B lineage and myeloid markers (49, 50). Other examples of the coexpression of B- and myeloid-associated antigens by human leukemic cells have recently been reviewed (37).

If our interpretation of these data is correct, it would be expected that cell lines that display clear, albeit early, markers of commitment to either the B cell or myeloid pathways of differentiation might also exhibit potential to mature within either lineage. Evidence for this comes from recent studies of single-cell cloned progeny of HAFTL1 (Table II). Stimulation of some clones with LPS results in induction of multiple \( JH \) rearrangements and the sequential expression of \( ThB \) and Ia, events associated with maturation within the B cell lineage (Fig. 1). By comparison, other clones develop characteristics of mature macrophages (Davidson, W. F., J. H. Pierce, S. Rudikoff, and H. C. Morse, III; manuscript in preparation).

In conclusion, these studies indicate that an unexpectedly wide range of onc genes can induce B lineage lymphomas in vitro. The availability of cell lines with both myeloid and B cell differentiation potentials provides a unique opportunity to explore the molecular and biochemical events that define irrevocable commitment to these distinct hematopoietic lineages.

**Summary**

In vitro infection of bone marrow or fetal liver cells with retroviruses containing \( fes, abl, ras, \) or \( src \) oncogenes resulted in the transformation of early B lineage cells. All cell lines tested possessed rearrangements at the Ig heavy chain locus and some had rearrangements at the \( \kappa \) chain locus. The majority of the lines corresponded phenotypically to Lyb-2\(^+\), Ly-5(B220)\(^-\), ThB\(^-\) large pre-B cells, although some were classified as pro-B cells because of their Lyb-2\(^+\), Ly-17\(^+\), Ly-5(B220)\(^-\) phenotype. We identified two cell lines that contained subpopulations of cells that coexpressed the B lineage antigens Lyb-2 and Ly-5(B220) and the myeloid lineage antigen Mac-1. Single-cell FMF cloning of these subpopulations showed that Mac-1\(^+\) cells were derived from Mac-1\(^-\) cells and that these Mac-1\(^+\)-cloned cells further differentiated into cells with phenotypic and functional characteristics of mature macrophages.

We wish to acknowledge the expert technical assistance of Mr. Chuck Knicely.

*Received for publication 25 February 1986.*

**References**

1. Siden, E., D. Baltimore, P. Clark, and N. Rosenberg. 1979. Immunoglobulin synthesis by lymphoid cells transformed in vitro by Abelson murine leukemia virus. *Cell.* 16:389.
2. Pierce, J. H., and S. A. Aaronson. 1983. In vitro transformation of murine pre-B lymphoid cells by Snyder-Theilen feline sarcoma virus. *J. Virol.* 46:993.

3. Shih, T. Y., M. O. Weeks, H. A. Young, and E. M. Scolnick. 1979. p21 of Kirsten murine sarcoma virus is thermostable in a viral mutant temperature sensitive for the maintenance of transformation. *J. Virol.* 31:546.

4. Pierce, J. H., and S. A. Aaronson. 1982. Balb- and Harvey-murine sarcoma virus transformation of a novel lymphoid progenitor cell. *J. Exp. Med.* 156:873.

5. Pierce, J. H., and S. A. Aaronson. 1985. Myeloid cell transformation by ras-containing murine sarcoma viruses. *Molec. Cell. Biol.* 5:667.

6. Pierce, J. H., S. A. Aaronson, and S. M. Anderson. 1984. Hematopoietic cell transformation by a murine recombinant retrovirus containing the src gene of Rous sarcoma virus. *Proc. Natl. Acad. Sci. USA.* 81:2374.

7. Morse, H. C., III, T. M. Chused, M. Boehm-Truitt, B. J. Mathieson, S. O. Sharrow, and J. W. Hartley. 1979. *xenCSA*: cell surface antigens related to the major glycoproteins (gp70) of xenotropic murine leukemia viruses. *J. Immunol.* 122:443.

8. Yeh, C.-J. G., B.-L. Hsi, and W. P. Faulk. 1981. Propidium iodide as a nuclear marker in immunofluorescence. II. Use with cellular identification and viability studies. *J. Immunol. Methods.* 43:269.

9. Ledbetter, J. A., and L. A. Herzenberg. 1979. Xenogenic monoclonal antibodies to mouse lymphoid differentiation antigens. *Immunol. Rev.* 47:63.

10. Subbarao, B., and D. E. Mosier. 1983. Induction of B lymphocyte proliferation by monoclonal anti-Lyb-2 antibody. *J. Immunol.* 130:2033.

11. Coffman, R. L. 1982. Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-B cell development. *Immunol. Rev.* 69:5.

12. Symington, F. W., B. Subbarao, D. E. Mosier, and J. Sprent. 1982. Lyb-8.2: a new B cell antigen defined and characterized with a monoclonal antibody. *Immunogenetics.* 16:381.

13. Unkeless, J. 1979. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. *J. Exp. Med.* 150:580.

14. Holmes, K. L., R. G. E. Palfree, U. Hammerling, and H. C. Morse, III. 1985. Alleles of the Ly-17 alloantigen define polymorphisms of the murine IgG Fc receptor. *Proc. Natl. Acad. Sci. USA.* 82:7706.

15. Shen, F.-W., and E. A. Boyse. 1980. An alloantigen selective for B cells: Ly 17.1. *Immunogenetics.* 11:115.

16. Oi, V. T., P. P. Jones, J. W. Goding, L. A. Herzenberg, and L. A. Herzenberg. 1978. Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. *Curr. Top. Microbiol. Immunol.* 81:115.

17. Springer, T., G. Galfre, D. S. Secher, and C. Milstein. 1979. Mac-1: a macrophage differentiation antigen identified by monoclonal antibody. *Eur. J. Immunol.* 9:301.

18. Ho, M.-K., and T. A. Springer. 1982. Mac-2, a novel 32,000 M, mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. *J. Immunol.* 128:1221.

19. Springer, T. A., and M.-K. Ho. 1982. Macrophage differentiation antigens: markers of macrophage subpopulations and tissue localization. In *Progress in Cancer Research and Therapy.* Vol. 21. M. S. Mitchell and H. F. Oettgen, editors. Raven Press, New York. 35-46.

20. Pillemere, E., C. Whitlock, and I. L. Weissman. 1984. Transformation-associated proteins in murine B-cell lymphomas that are distinct from Abelson virus gene products. *Proc. Natl. Acad. Sci. USA.* 81:4434.

21. Lang, R. B., L. W. Stanton, and K. B. Marcu. 1982. On immunoglobulin heavy chain
gene switching: two γ2b genes are arranged via switch sequences in MPC-11 cells but only one is expressed. Nucleic Acids Res. 10:611.
22. Coleclough, C., R. P. Perry, K. Karjalainen, and M. Weigert. 1981. Aberrant rearrangements contribute significantly to the allelic exclusion of immunoglobulin gene expression. Nature (Lond.). 290:372.
23. Davidson, W. F., T. N. Fredrickson, E. K. Rudikoff, R. L. Coffman, J. W. Hartley, and H. C. Morse, III. 1984. A unique series of lymphomas related to the Ly-1+ lineage of B lymphocyte differentiation. J. Immunol. 133:744.
24. Holmes, K. L., and H. C. Morse, III. 1984. Coexpression of Lyb-2 and Mac-1 by murine lymphomas and subpopulations of normal spleen and bone marrow cells. Curr. Top. Microbiol. Immunol. 113:224.
25. Lala, P. K., G. R. Johnson, F. L. Battye, and G. J. V. Nossal. 1979. Maturation of B lymphocytes. I. Concurrent appearance of increasing Ig, Ia, and mitogen responsiveness. J. Immunol. 122:334.
26. Hammerling, U., A. F. Chin, and J. Abbott. 1976. Ontogeny of murine B lymphocytes: sequence of B-cell differentiation from surface-immunoglobulin-negative precursors to plasma cells. Proc. Natl. Acad. Sci. USA. 73:2008.
27. Manohar, V., E. Brown, W. M. Leiserson, and T. M. Chused. 1982. Expression of Lyt-1 by a subset of B lymphocytes. J. Immunol. 129:532.
28. Hayakawa, K., R. R. Hardy, D. R. Parks, and L. A. Herzenberg. 1983. The "Ly-1 B" cell subpopulation in normal immunodeficient and autoimmune mice. J. Exp. Med. 157:202.
29. Hardy, R. R., L. A. Herzenberg, H. C. Morse, III, W. F. Davidson, and L. A. Herzenberg. 1984. Ly-1 as a differentiation antigen on normal and neoplastic B cells. Curr. Top. Microbiol. Immunol. 113:331.
30. Hayakawa, K., R. R. Hardy, L. A. Herzenberg, and L. A. Herzenberg. 1985. Progenitors for Ly-1 B cells are distinct from progenitors for other B cells. J. Exp. Med. 161:1554.
31. Tidmarsh, G. F., M. O. Dailey, C. A. Whitlock, E. Pillemer, and I. L. Weissman. 1985. Transformed lymphocytes from Abelson-diseased mice express levels of a B lineage transformation-associated antigen elevated from that found on normal lymphocytes. J. Exp. Med. 162:1421.
32. Schrader, J. W., F. Battye, and R. Scollay. 1982. Expression of Thy-1 antigen is not limited to T cells in cultures of mouse hemopoietic cells. Proc. Natl. Acad. Sci. USA. 79:4161.
33. Ihle, J. N., H. C. Morse, III, J. Keller, and K. L. Holmes. 1984. Interleukin 3 dependent retrovirus induced lymphomas: loss of the ability to terminally differentiate in response to differentiation factors. Curr. Top. Microbiol. Immunol. 113:86.
34. Boss, M., M. Greaves, and N. Teich. 1982. Abelson virus transforms hematopoietic stem cell virus with pre-B cell characteristics. Nature (Lond.). 278:551.
35. Kurtzberg, J., S. H. Bigner, and M. S. Hershfield. 1985. Establishment of the DU.528 human lymphohemopoietic stem cell line. J. Exp. Med. 162:1561.
36. McCulloch, E. A. 1983. Stem cells in normal and leukemic hemopoiesis. Blood. 62:1.
37. Greaves, M. F., L. C. Chan, A. J. W. Furley, S. M. Watt, and H. V. Molgaard. 1986. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood. 67:1.
38. Till, J. E. 1976. Regulation of hemopoietic stem cells. In Stem Cells of Renewing Cell Populations. A. B. Cairnie, P. K. Lala, and D. G. Osmond, editors. Academic Press, New York. 143–155.
39. Holmes, K. L., W. Y. Langdon, T. N. Fredrickson, R. L. Coffman, P. M. Hoffman, J. W. Hartley, and H. C. Morse, III. 1986. Analysis of neoplasms induced by Cas-Br-M MuLV tumor extracts. J. Immunol. In press.
40. Bauer, S. R., K. L. Holmes, H. C. Morse, III, and M. Potter. 1986. Clonal relationship of the lymphoblastic cell-line P388 to the macrophage cell-line P388D1 as evidenced by immunoglobulin gene rearrangements and expression of cell surface antigens. J. Immunol. 136:4695.

41. Velardi, A., and M. D. Cooper. 1984. An immunofluorescence analysis of the ontogeny of myeloid, T, and B lineage cells in mouse hemopoietic tissues. J. Immunol. 133:672.

42. Boyd, A. W., and J. W. Schrader. 1982. Derivation of macrophage-like lines from the pre-B lymphoma ABLS 8.1 using 5-azacytidine. Nature (Lond.). 297:691.

43. Stong, R. C., S. J. Korsmeyer, J. L. Parkin, D. C. Arthur, and J. H. Kersey. 1985. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood. 65:21.

44. Bakhshi, A., J. Minowada, A. Arnold, J. Cossman, J. P. Jensen, J. Whang-Peng, T. A. Waldmann, and S. J. Korsmeyer. 1983. Lymphoid blast crises of chronic myelogenous leukemia represent stages in the development of B-cell precursors. N. Engl. J. Med. 309:826.

45. Griffin, J. D., R. F. Todd, III, J. Ritz, L. M. Nadler, G. P. Canellos, D. Rosenthal, M. Gallivan, R. P. Beveridge, H. Weinstein, D. Karp, and S. F. Schlossman. 1985. Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 61:85.

46. Minowada, J., H. Koshiba, G. Janossy, M. F. Greaves, and F. J. Bollum. 1979. A Philadelphia chromosome positive human leukaemia cell line (NALM-1) with pre-B characteristics. Leuk. Res. 3:261.

47. Martin, P. J., V. Najifield, J. A. Hansen, G. K. Penfold, R. J. Jacobson, and P. J. Fialkow. 1980. Involvement of the B lymphoid system in chronic myelogenous leukemia. Nature (Lond.). 287:49.

48. Neame, P. B., P. Soamboonsrup, G. Growman, R. D. Barr, N. Saeed, B. Chan, M. Pui, A. Benger, W. E. C. Wilson, I. R. Walker, and J. A. McBride. 1985. Simultaneous or sequential expression of lymphoid and myeloid phenotypes in acute leukemia. Blood. 65:142.

49. Perentesis, J., N. K. C. Ramsay, R. Brunning, J. H. Kersey, and A. H. Filipovich. 1983. Biphenotypic leukemia: Immunologic and morphologic evidence for a common lymphoid-myeoid progenitor in humans. J. Pediatr. 102:63.

50. Pui, C.-H., G. V. Dahl, S. Melvin, D. L. Williams, S. Peiper, J. Mirro, S. B. Murphy, and S. Stass. 1984. Acute leukaemia with mixed lymphoid and myeloid phenotype. Br. J. Haematol. 56:121.